Baker Bros. Advisors LP Invitae Corp Transaction History

Baker Bros. Advisors LP

$7.9 Billion
Q1 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.6 - $1.53 $4.27 Million - $10.9 Million	-7,116,558 Reduced 80.13%	1,764,546 $1.06 Million
Q1 2023 May 15, 2023	BUY	$1.2 - $2.73 $574,882 - $1.31 Million	479,069 Added 5.7%	8,881,104 $12 Million
Q3 2022 Nov 14, 2022	SELL	$1.9 - $8.63 $2.8 Million - $12.7 Million	-1,471,453 Reduced 14.9%	8,402,035 $20.7 Million
Q3 2021 Nov 15, 2021	SELL	$24.31 - $33.6 $9.12 Million - $12.6 Million	-375,087 Reduced 3.66%	9,873,488 $281 Million
Q2 2021 Aug 16, 2021	SELL	$26.09 - $40.4 $144 Million - $222 Million	-5,500,607 Reduced 34.93%	10,248,575 $346 Million

Q1 2021 May 17, 2021	BUY	$33.06 - $56.93 $3.31 Million - $5.69 Million	100,000 Added 0.64%	15,749,182 $602 Million
Q4 2020 Feb 16, 2021	BUY	$39.09 - $57.4 $148 Million - $218 Million	3,798,220 Added 32.05%	15,649,182 $654 Million
Q2 2020 Aug 14, 2020	BUY	$11.71 - $30.29 $32.2 Million - $83.3 Million	2,750,347 Added 30.22%	11,850,962 $359 Million
Q1 2020 May 15, 2020	BUY	$7.64 - $27.5 $26,358 - $94,875	3,450 Added 0.04%	9,100,615 $124 Million
Q4 2019 Feb 14, 2020	BUY	$15.02 - $20.57 $4.57 Million - $6.26 Million	304,487 Added 3.46%	9,097,165 $147 Million
Q3 2019 Nov 14, 2019	BUY	$18.85 - $27.5 $92.2 Million - $134 Million	4,890,257 Added 125.31%	8,792,678 $169 Million
Q4 2018 Feb 13, 2019	SELL	$9.26 - $16.38 $41.6 Million - $73.7 Million	-4,496,990 Reduced 53.54%	3,902,421 $43.2 Million
Q1 2018 May 15, 2018	BUY	$4.69 - $10.05 $5.21 Million - $11.2 Million	1,111,111 Added 15.25%	8,399,411 $39.4 Million
Q3 2017 Nov 14, 2017	BUY	$8.89 - $10.4 $64.8 Million - $75.8 Million	7,288,300	7,288,300 $68.3 Million

Others Institutions Holding NVTA

# of Institutions

Shares Held

7.66M

Call Options Held

Put Options Held

View Full List

About Invitae Corp

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

More about NVTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Account